Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kyle George

Physician Assistant, Medical Meridian, ID Physician Assistant

NPI 1225220643 CMS profile 11138202

520 S Eagle Rd Ste 3211, Meridian, ID 83642

Open in the dashboard

General payments

$19,100

214 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle George of Meridian, ID is reported in the CMS Open Payments database as having received $19,100 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,962 93
2024 General $7,902 66
2023 General $1,201 13
2022 General $5,646 34
2021 General $389 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle George
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kyle George were reported at $3,962. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kyle George Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $389 $156 $41–$563 $132
2022 $5,646 $185 $55–$649 $149
2023 $1,201 $199 $58–$717 $160
2024 $7,902 $206 $62–$740 $164
2025 $3,962 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $4,973 15 payments
  2. UCB, Inc. $2,630 25 payments
  3. AstraZeneca Pharmaceuticals LP $2,246 10 payments
  4. Amgen Inc. $1,991 67 payments
  5. Janssen Biotech, Inc. $1,827 17 payments
  6. Mallinckrodt Hospital Products Inc. $1,578 4 payments
  7. Novartis Pharmaceuticals Corporation $1,539 5 payments
  8. AbbVie, Inc. $1,083 39 payments
  9. Lilly USA, LLC $503 8 payments
  10. Janssen Scientific Affairs, LLC $302 4 payments
  11. Other $427 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $11,105 10 payments
  2. Food and Beverage $5,760 190 payments
  3. Travel and Lodging $1,925 8 payments
  4. Education $310 6 payments
Products named General payments · program years 2021–2025
  1. OFEV $4,202 13 payments
  2. SAPHNELO $2,226 9 payments
  3. TREMFYA $2,129 21 payments
  4. ACTHAR $1,578 4 payments
  5. COSENTYX $1,539 5 payments
  6. SIMPONI ARIA $1,441 3 payments
  7. Otezla $1,266 33 payments
  8. RINVOQ $798 30 payments
  9. Bimzelx $645 14 payments
  10. EVENITY $300 14 payments
  11. Other $1,893 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

992

Median for Physician Assistant: 241

Drug cost

$589,644

Median for Physician Assistant: $4,110

Branded share of claims

25.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 29 $280,435
Humira(Cf) Pen Adalimumab Brand 24 $159,415
Enbrel Mini Etanercept Brand 12 $109,972
Leflunomide Generic 81 $11,709
Hydroxychloroquine Sulfate Generic 189 $10,282
Celecoxib Generic 65 $5,397
Methotrexate Methotrexate Sodium Brand 189 $4,675
Pilocarpine Hcl Generic 17 $2,745
Prednisone Generic 165 $1,299
Azathioprine Generic 12 $840

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$16,329

Medicare's payments for the services billed

Medicare patients

192

Average age 72

Services billed

769

133 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Osteoporosis 36%
Depression 27%
Diabetes 24%
Chronic kidney disease 18%
Ischemic heart disease 16%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $4,202
$4,202 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $1,539
$1,539 — —
TREMFYA
  • Janssen Biotech, Inc. $210
$210 — —
EVENITY
  • Amgen Inc. $165
$165 — —
Bimzelx
  • UCB, Inc. $114
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record